Clovis Oncology Inc. (NASDAQ:CLVS) is an active participant in the development of innovative anti-cancer agents. It has a strong presence in the U.S., Europe, and other international markets. Its development programs primarily target subsets of cancer populations. The company is now on its Phase 2 Portion trial of LIO-1 as it evaluates its combination of lucitanib.
The LIO-1 trial is part of Clovis’ broad clinical collaboration with Bristol Myers Squibb. On the other hand, lucitanib is an investigational angiogenesis inhibitor but an unlicensed medical product.
The anticipation to Have LIO-1 as a Treatment for Advanced Gynecological Solid Tumors
“… nearly 100,000 women will be diagnosed with gynecologic cancer in the U.S. this year alone, and it is vital that we identify new treatment options, in particular new combinations, for these women,” the Director of the Breast and Gynecologic Research Program, Dr. Erika Hamilton explained.
A majority of the gynecologic cancers come with tumors. This emphasizes the importance of the Phase 2 part of LIO-1 open-label study and particularly the effects of lucitanib and Opdivo. If found safe, this would be an optional treatment for advanced gynecological solid tumors. It would also be considered for other illnesses, including ovarian and endometrial subtypes such as cell diseases and cervical cancer.
Results from the just-concluded Phase 1b dose-escalation portion of the LIO-1 study were promising. They formed the basis for a Phase 2 dosing regimen as well as a trials-in-progress description.
The Commitment to Pursue Innovative Clinical Studies
Together with his team, the CEO of Clovis Oncology, Patrick J. Mahaffy, says they are optimistic about expanding the company’s portfolio with innovative products. However, this will be accomplished through advanced clinical studies that should target both monotherapy and in combination.
Meanwhile, the Clovis says it is actively engaging in collaborations and other potential in-licensing opportunities, likely to bring on board cancer therapeutics. With the current global struggle with COVID-19, collaborations have become common as more companies race with time to develop viable vaccines for the virus. This will be one way of quickening the development activities.
